Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity - Wikidata - awgldk - TriplyDB

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity

http://www.wikidata.org/entity/Q39186710

about

Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscape Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.HIV-1 Transmission, Replication Fitness and Disease Progression."Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance.Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users SiRNA-induced mutation in HIV-1 polypurine tract region and its influence on viral fitness.Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.HIV-1 antiretroviral drug therapy.Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape.Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells.HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120 HIV-1 drug resistance mutations: an updated framework for the second decade of HAART Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation.Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques.Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.HIV-1 Entry, Inhibitors, and Resistance Position 22 of the V3 loop is associated with HIV infectivity.Conserved determinants of enhanced CCR5 binding in the human immunodeficiency virus subtype D envelope third variable loop.HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers.Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies.

P2860

Q21131580-C0B9650B-3424-44A8-9382-2879844EB49D Q26851997-3E17251A-080D-48BB-8CE2-F6FC13712C9B Q28477409-2DD7ADCB-7537-4E52-B817-7C74074AC6F5 Q28487168-A54E0EF2-DC74-490D-9765-76E93874FD44 Q28541754-E7137D75-CD4D-4B69-A540-C60E680C24E8 Q33429049-E0217844-D18B-4BF7-9EA2-89333FA536E8 Q33622927-B675D3D9-B09D-4085-99BF-D7DBC68B47A6 Q33758570-289B7F82-D426-4869-8A6A-D00323F94B11 Q33877312-93565F11-F85A-44E3-9154-66D7162FDAA2 Q34120878-28D1E7E5-B507-4BC1-98CC-50FC2C1D8E5D Q34620235-500B9FA8-D176-431E-A3BB-C68FC8580E1B Q35362902-BBADAA20-DB04-4BB2-8E36-B14A8C4CBB1D Q35383268-3C23D8B3-E278-4986-A068-E5504FA84BC4 Q35853012-D338EEE0-9987-4EBD-B0B4-8BC0977CA521 Q36315529-3675A372-0153-4D86-8929-C9B2A3EBA967 Q36466404-FC521613-8132-4F71-921D-7A93DBB40D02 Q36502557-B8A9884C-6489-40E7-914F-9EE17C743773 Q36558933-6D752B3E-B02C-4062-8012-BC500E61CD83 Q36559608-E4785291-F58C-49EF-8068-71D6E33B10E3 Q36900010-661B7410-2EF7-481B-B5FF-030EFD1C0510 Q37026646-874F4C4B-C84F-4076-9947-C0E5AF468E7B Q37157165-7CB9B8CA-4B82-44F5-B24D-BFC5753BBFDA Q37192119-E2E2842B-BD8F-492D-8ACE-7F91B69ABD77 Q37356028-E0F4507E-3693-493F-BAAB-0CA9F629B681 Q37410812-940E49D5-A769-455E-BE3F-60EC385B7DF6 Q37444204-7B040F60-269B-493B-A590-A4751A150F44 Q37945205-484F5D94-ACF2-43A8-98DC-D3D70B659751 Q38732857-4248C4AC-D081-43CC-B2A2-E21D31EF947B Q39717223-48E0683F-AD6A-4CA2-868A-6A1C58CBEAA0 Q40797960-C15033B0-2981-4DB9-B383-C4604779D0C7 Q42348438-2F1C972D-609D-41E6-94DD-0FB74ECFE545 Q42718488-5D5A6FE8-8BD2-4DE8-ABF9-B6D28F782748 Q47193141-9700FB91-30A3-40E5-AD68-1E938020C173

P2860

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity

http://www.wikidata.org/entity/Q39186710

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Natural variation in the V3 cr ...... nd entry inhibitor sensitivity

@en

Natural variation in the V3 cr ...... d entry inhibitor sensitivity.

@nl

type

label

Natural variation in the V3 cr ...... nd entry inhibitor sensitivity

@en

Natural variation in the V3 cr ...... d entry inhibitor sensitivity.

@nl

prefLabel

Natural variation in the V3 cr ...... nd entry inhibitor sensitivity

@en

Natural variation in the V3 cr ...... d entry inhibitor sensitivity.

@nl

P1433

Q39186710-1D6573BB-ABAC-4F82-A050-F7F68C5CD049

P1476

Q39186710-2E89F1A1-95FA-44E5-A76B-D06A740B6A40

P2093

Q39186710-11F10CBA-B6CF-41D4-9E4C-A57F718111C8

Q39186710-68E76A0A-5E40-4874-B6AC-36CBE541C181

Q39186710-A4ECF3E5-55E5-4229-9C00-9CCD3D962127

Q39186710-ED19BEAC-B558-47DD-B1AA-C99890771C0C

P2860

Q39186710-025281D0-CA8D-4D16-B6DB-8A22F531C4CC

Q39186710-0763253D-9567-4873-BD1B-7B31DE05225C

Q39186710-0E742951-0989-44AE-85BC-8BBC5C4B16F4

Q39186710-13B09687-95E9-4E38-AD74-E0E6BA0BC6D7

Q39186710-1472DAE7-9D9D-4BC0-B1B0-F4E429899CEB

Q39186710-17FE64F4-A3C8-41A9-977E-5BDB493080CE

Q39186710-1A76B440-3D8B-4E18-8C56-8D6F4F2F5B1C

Q39186710-1B5398CB-7C56-4409-A31D-977A98D41499

Q39186710-1E3059C3-7C4E-4762-BECA-72A59EF51AA0

Q39186710-23B9AC53-C14F-4CE4-97F6-D8B8A93A97BD

P304

Q39186710-81CDE3E5-B2CA-4C73-BD71-A5C7C5C41814

P31

Q39186710-09FE2D08-79CF-4C40-B824-EA62938B49A1

P356

Q39186710-5400AD90-E8CD-4F5B-B7EB-27D422675A5A

P407

Q39186710-F5B85B0B-8A9D-44A7-8161-87CD0169921E

P433

Q39186710-07E2A7FA-A1C6-4090-8B2B-B0A126BC55A7

P478

Q39186710-C37A8AF6-D02B-40B4-8A6D-3EC4AC7FC504

P577

Q39186710-DE25C7C0-3DBB-4BA5-A9A4-1F9E19F5C965

P5875

Q39186710-092863DE-8ADC-4B54-B8C5-8319269A5E9D

P698

Q39186710-99004849-2116-47FC-9F77-8185EF25DDF7

P932

Q39186710-C948CFE2-D7AC-41E3-AEE5-73BF60704601

P356

P1433

Journal of Virology

P1476

Natural variation in the V3 cr ...... nd entry inhibitor sensitivity

@en

P2093

Andre J Marozsan

http://www.w3.org/2001/XMLSchema#string

Eric J Arts

http://www.w3.org/2001/XMLSchema#string

Michael A Lobritz

http://www.w3.org/2001/XMLSchema#string

Ryan M Troyer

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

Mechanisms of viral membrane fusion and its inhibition

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

Structure of a V3-containing HIV-1 gp120 core

Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus

P304

8258-8269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02739-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6311040

http://www.w3.org/2001/XMLSchema#string

P698

17522224

http://www.w3.org/2001/XMLSchema#string

P932

1951322

http://www.w3.org/2001/XMLSchema#string